Journal
EMERGING INFECTIOUS DISEASES
Volume 18, Issue 1, Pages 120-124Publisher
CENTERS DISEASE CONTROL & PREVENTION
DOI: 10.3201/eid1801.110515
Keywords
-
Categories
Funding
- Canadian Institutes of Health Research
- Abbott Laboratories Ltd.
Ask authors/readers for more resources
To assess molecular evolution of the respiratory syncytial virus (RSV) fusion gene, we analyzed RSV-positive specimens from 123 children in Canada who did or did not receive RSV immunoprophylaxis (palivizumab) during 2006-2010. Resistance-conferring mutations within the palivizumab binding site occurred in 8.7% of palivizumab recipients and none of the nonrecipients.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
